Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Cetuximab + Cisplatin + Epirubicin + Fluorouracil|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Cetuximab||Erbitux||IMC-C225||EGFR Antibody 29||Erbitux (cetuximab) is a monoclonal antibody directed against EGFR, which inhibits signal transduction and cell proliferation (PMID: 28695301). Erbitux (cetuximab) is FDA approved for use in head and neck squamous cell carcinoma and KRAS wild-type, EGFR positive colorectal cancer (FDA.gov).|
|Cisplatin||Platinol||CDDP||Chemotherapy - Platinum 6||Platinol (cisplatin) is a platinum based chemotherapeutic, which is FDA approved for bladder, ovarian, and testicular cancers (NCI Drug Dictionary).|
|Epirubicin||Ellence||Epirubicin Hydrochloride||Chemotherapy - Anthracycline 11||Ellence (epirubicin) is an anthracycline, which intercalates into DNA and inhibits topoisomerase II (PMID: 24367159). Ellence (epirubicin) is FDA approved as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement for primary breast cancer (FDA.gov).|
|Fluorouracil||Adrucil||5-FU||Chemotherapy - Antimetabolite 11||Adrucil (fluorouracil) is an antimetabolite chemotherapeutic agent, which interferes with DNA and RNA synthesis thereby preventing cancer cell growth and is FDA approved for colorectal, breast, stomach, and pancreatic cancer (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||gastrointestinal system cancer||not applicable||Cetuximab + Cisplatin + Epirubicin + Fluorouracil||Phase II||Actionable||In a Phase II trial, Erbitux (cetuximab) in combination with ECF (epirubicin, cisplatin, and fluorouracil) resulted in an overall response rate of 60.9% (38/63), median overall survival of 11.6 months; and median progression-free survival of 7.1 months in patients with metastatic esophageal or gastroesophageal junction cancers (PMID: 27382098).||27382098|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|